Method of treating androgen independent prostate cancer
AssigneeNatrogen Therapeutics International, Inc.
InventorsLonggui Wang, Simon K. Mencher, James P. McCarron, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.
Claims20
A method of treating advanced stage prostate cancer, the method comprising administering a compound to a patient in need thereof, wherein the prostate cancer is hormone refractory and/or metastatic and the compound is selected from the group consisting of:
- and the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.
A method of treating advanced stage prostate cancer, the method comprising administering to a patient having hormone refractory and/or metastatic prostate cancer a compound selected from the group consisting of:
- N-methyl-Δ3,3′-dihydroindole-2,2′ diketone;
- N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone;
- or N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone, wherein the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.
Dependencies are inferred from the claim text.